Aprea Therapeutics GAAP EPS of -$0.07 beats by $0.16 (APRE:NASDAQ)
· seekingalpha.com
Aprea Therapeutics (APRE) Q2 GAAP EPS beats estimates; cash rises to $41.2M, runway into Q1 2028.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...